Clinical Trials > CHAMPion  

  • Information
  • Links


Cancer-induced Hypercoagulability as a marker of prognosis

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Recruitment
II Observation Open 18 and over University of South Manchester Eudract No:
Isrctn No:


Prospective clinical cohort study investigating durtion and significance of hypercoagulable response to surgery, correlated with tumour molecular phenotype and outcome. Pre ans post-operative plasma markers of clotting cascade activation, platelet activation, fibronolytic activity and activation of coagulation will be compared to tissue expression of equivalent markers, development of clinical VTE, tumour clinicopathological prognostic factors, and survival in patients undergoing elective abdominal and breast cancer surgery. Patients undergoing non-cancer surgery (matched for age, sex and type of surgery to the cancer patients) will provide baseline response to surgery.

Trial Lead Organisations

University of South Manchester

Trial Start Date

Trial Not Open

Trial Coordinator

Gemma Nanson

Trial Coordinator Email Address

Trial Coordinator Contact No

0151 794 8974




Lost Username / Password?